<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">32050</article-id><article-id pub-id-type="doi">10.17116/terarkh201688931-38</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Lipoprotein(a), its autoantibodies, and circulating T lymphocyte subpopulations as independent risk factors for coronary artery atherosclerosis</article-title><trans-title-group xml:lang="ru"><trans-title>Липопротеид(а), аутоантитела к нему и циркулирующие субпопуляции Т-лимфоцитов как независимые факторы риска атеросклероза коронарных артерий</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Afanasievа</surname><given-names>O I</given-names></name><name xml:lang="ru"><surname>Афанасьева</surname><given-names>О И</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pylaeva</surname><given-names>E A</given-names></name><name xml:lang="ru"><surname>Пылаева</surname><given-names>Е А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Klesareva</surname><given-names>E A</given-names></name><name xml:lang="ru"><surname>Клесарева</surname><given-names>Е А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Potekhina</surname><given-names>A V</given-names></name><name xml:lang="ru"><surname>Потехина</surname><given-names>А В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Provatorov</surname><given-names>S I</given-names></name><name xml:lang="ru"><surname>Проваторов</surname><given-names>С И</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Afanasieva</surname><given-names>M I</given-names></name><name xml:lang="ru"><surname>Афанасьева</surname><given-names>М И</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Krasnikova</surname><given-names>T L</given-names></name><name xml:lang="ru"><surname>Красникова</surname><given-names>Т Л</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Masenko</surname><given-names>V P</given-names></name><name xml:lang="ru"><surname>Масенко</surname><given-names>В П</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Arefieva</surname><given-names>T I</given-names></name><name xml:lang="ru"><surname>Арефьева</surname><given-names>Т И</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pokrovsky</surname><given-names>S N</given-names></name><name xml:lang="ru"><surname>Покровский</surname><given-names>С Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Российский кардиологический научно-производственный комплекс Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-09-15" publication-format="electronic"><day>15</day><month>09</month><year>2016</year></pub-date><volume>88</volume><issue>9</issue><issue-title xml:lang="en">VOL 88, NO9 ()</issue-title><issue-title xml:lang="ru">ТОМ 88, №9 (2016)</issue-title><fpage>31</fpage><lpage>38</lpage><history><date date-type="received" iso-8601-date="2020-04-10"><day>10</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/32050">https://ter-arkhiv.ru/0040-3660/article/view/32050</self-uri><abstract xml:lang="en"><p>Aim. To study the role of lipoprotein(a) [Lp(a)] as a potential autoantigen causing the activation of immunocompetent cells in atherosclerosis. Subjects and methods. A total of 104 men with stable coronary artery (CA) disease and different degrees of progressive coronary atherosclerosis were examined. Clinical blood analysis was carried out and lymphocyte subpopulations (CD4+, Th1, Th17, and Treg) were determined using immunofluorescence and flow cytometry. In addition, the indicators of blood lipid composition, Lp(a), autoantibody (autoAb) titer to Lp(a), and low-density lipoproteins (LDL), and the lymphocyte activation marker sCD25 were also measured. Results. The Lp(a) level was shown to predict the severity of CA lesions (β=0.28, p&lt;0.05), regardless of age, the level of cholesterol, different T-lymphocyte subpopulations, sCD25, and autoAb. A combination of the concentration of Lp(a) above 11.8 mg/dl, that of Th17 over 11.4∙103 cells/ml and the reduced levels of regulatory T cells and IL-10-producing CD4+ T cells showed a manifold increase in the risk of severe and progressive CA atherosclerosis. There was a direct correlation of the blood level of Th1 with that of IgG autoAb specific to all atherogenic apoB-containing lipoproteins, including Lp(a). There was an inverse correlations of the lymphocyte activation marker sCD25 with IgM anti-Lp(a) autoAb titers (r=–0.36; p&lt;0.005), but this was less significant with autoAbs to native and oxidized LDL (r=–0.21 and r=–0.24; p&lt;0.05, respectively). Conclusion. The slightly elevated Lp(a) concentration along with changes in the level of T lymphocyte subpopulations was first shown to significantly potentiate the risk of progressive and multiple CA lesion in the examinees. The correlation of IgM anti-Lp(a) autoAb with the lymphocyte activation marker sCD25 and that of IgG anti-Lp(a) autoAb with Th1 have demonstrated that Lp(a) is involved in the autoimmune inflammatory processes in atherosclerosis.</p></abstract><trans-abstract xml:lang="ru"><p>Резюме Цель исследования — изучить роль липопротеида(а) [Лп(а)] как потенциального аутоантигена, вызывающего активацию иммунокомпетентных клеток при атеросклерозе. Материалы и методы. Обследовали 104 мужчин со стабильной формой ишемической болезни сердца и различной степенью прогрессии коронарного атеросклероза. Выполняли общий анализ крови и определение субпопуляций лимфоцитов (CD4+, Th1, Th17, Tрег) с помощью иммунофлюоресценции и поточной цитометрии. Кроме того, измеряли показатели липидного состава крови, Лп(а), титр аутоантител (аутоАТ) к Лп(а) и липопротеиды низкой плотности (ЛНП), маркер активации лимфоцитов sCD25. Результаты. Уровень Лп(а) являлся предиктором тяжести поражений коронарных артерий — КА (β=0,28; p&lt;0,05) независимо от возраста, уровня холестерина, содержания различных субпопуляций Т-лимфоцитов, sCD25 и аутоАТ. Сочетание у пациента концентрации Лп(а) более 11,8 мг/дл и Th17 более 11,4 тыс./мл как и сниженных показателей регуляторных Т-лимфоцитов и Т-лимфоцитов CD4+, продуцирующих интерлейкин-10, многократно увеличивало риск развития тяжелого и прогрессирующего атеросклероза КА. Выявлена прямая взаимосвязь содержания в крови Th1 с уровнем аутоАТ класса IgG, специфичных ко всем атерогенным Лп, содержащим апоВ, включая Лп(а). Обнаружена обратная взаимосвязь показателя активации лимфоцитов sCD25 с титром аутоАТ класса IgM, специфичных к Лп(а) (r=–0,36; p&lt;0,005), менее выраженную — к нативным и окисленным ЛНП (r=–0,21 и r=–0,24; p&lt;0,05 соответственно). Заключение. Впервые показано, что незначительно повышенная концентрация Лп(а) на фоне сдвигов в содержании субпопуляций Т-лимфоцитов значительно потенцирует риск прогрессирующего и множественного поражения КА у обследованных больных. Взаимосвязь аутоАТ к Лп(а) класса IgМ с маркером активации лимфоцитов sCD25 и аутоАТ класса IgG с Тh1 демонстрируют участие Лп(а) в процессах аутоиммунного воспаления при атеросклерозе.</p></trans-abstract><kwd-group xml:lang="en"><kwd>lipoprotein(a) [Lp(a)]</kwd><kwd>anti-Lp(a) autoantibodies</kwd><kwd>T lymphocytes</kwd><kwd>atherosclerosis</kwd><kwd>coronary arteries</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>липопротеид(а)</kwd><kwd>аутоантитела</kwd><kwd>Т-лимфоциты</kwd><kwd>атеросклероз</kwd><kwd>коронарные артерии</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E–/– mice. Am J Pathol. 2000;157(6):1819-24. doi:10.1016/S0002-9440(10)64820-1</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Laurat E, Poirier B, Tupin E, Caligiuri G, Hansson GK, Bariéty J, Nicoletti A. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation. 2001;104(2):197-202. doi:10.1161/01.CIR.104.2.197</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol. 2010;134(1):33-46. doi:10.1016/j.clim.2009.07.002</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Gao Q, Jiang Y, Ma T, Zhu F, Gao F, Zhang P, et al. A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol. 2010;185(10):5820-5827. doi:10.4049/jimmunol.1000116</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133-1141. doi:10.1038/ni1261</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Liuzzo G, Trotta F, Pedicino D. Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown. Eur Heart J. 2013;34(8):556-559. doi:10.1093/eurheartj/ehs399</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>.	Климов А.Н. Аутоиммунная теория атерогенеза и концепция модифицированных липопротеидов. Вестник АМН СССР. 1990;11:30-36.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Gabriel Virella, Maria F. Lopes-VirellaюAtherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis. 2008;200:239-246. doi:10.1016/j.atherosclerosis.2008.03.025</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Carbone F, Nencioni A, Mach F et al. Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases. Thrombos Haemostas. 2013;109(5):769-975. doi:10.1160/TH12-10-0768</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Lehtimäki T, Lehtinen S, Solakivi T, Nikkilä M, Jaakkola O, Jokela H, Ylä-Herttuala S, Luoma JS, Koivula T, Nikkari T. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol. 1999;19(1):23-27. doi:10.1161/01.ATV.19.1.23</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssönen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;11;339(8798):883-887. doi:10.1016/0140-6736(92)90926-t</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Nordestgaard BG, Chapman MJ et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853. doi:10.1093/eurheartj/ehq386</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Int Med. 2013;273(1):6-30. doi:10.1111/j.1365-2796.2012.02592.x.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Marcovina SM, Koschinsky ML, Albers JJ, SkarlatosS . Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem. 2003;49(11):1785-1796. doi:10.1373/clinchem.2003.023689</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ежов М.В., Афанасьева О.И., Камбегова А.А., Афанасьева М.И., Трухачева Е.П., Наумов В.Г., Покровский С.Н. Роль факторов риска атеросклероза в развитии ишемической болезни сердца у мужчин молодого возраста. Терапевтический архив. 2009;5:50-53.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>van Dijk RA, Kolodgie F, Ravandi A, et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res. 2012;53(12):2773-2790. doi:10.1194/jlr.P030890</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Baldo G, Giunco S, Kontothanassis D et al. Different apoprotein(a) isoform proportions in serum and carotid plaque. Atherosclerosis. 2007;193(1):177-185. doi:10.1016/j.atherosclerosis.2006.06.006</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Афанасьева О.И., Клесарева Е.А., Левашов П.А., Берестецкая Ю.В., Ежов М.В., Артемьева Н.В., Покровский С.Н. Аутоантитела против липопротеида(а) у больных с ишемической болезнью сердца. Кардиология. 2014;54(6):4-8.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Афанасьева О.И., Адамова И.Ю., Беневоленская Г.Ф., Покровский С.Н. Иммуноферментный метод определения липопротеида(а). Бюллетень экспериментальной биологии и медицины. 1995;120(10):398-401. doi:10.1007/bf02444976</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest. 1968;97(Suppl.):77-89.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Hoffmann HJ. Malling TM, Topcu A,Ryder LP, Nielsen KR, Varming K, Dahl R, Omland O, Sigsgaard T. CD4dimCD25brightTreg cell frequencies above a standardized gating threshold are similar in asthmatics and controls. Cytometry. 2007;71(6):371-378. doi:10.1002/cyto.a.20389</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Ait-Oufella H, Sage AP, Mallat Z, Tedgui A. Adaptive (T and B Cells) Immunity and Control by Dendritic Cells in Atherosclerosis. Circ Res. 2014;114:1640-1660. doi:10.1161/CIRCRESAHA.114.302761</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Brusko TM, Wasserfall CH, Hulme MA, Cabrera R, Schatz D, Atkinson, MA. Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation. PLoS One. 2009;4(11):e7980. doi:10.1371/journal.pone.0007980</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Hoeger PH, Niggemann B, Ganschow R, Dammann C, Haeuser G. Serum levels of sCD23 and sCD25 in children with asthma and in healthy controls. Allergy. 1994;49(4):217-221. doi:10.1111/j.1398-9995.1994.tb02652.x</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Kyaw T, Tipping P, Bobik A, Toh BH. Protective role of natural IgM-producing B1a cells in atherosclerosis. Trends Cardiovasc Med. 2012;22:48-53. doi:10.1016/j.tcm.2012.06.011</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Kyaw T-, Tay C, Khan A, Dumouchel V, Cao A, To K, Kehry M, Dunn R, Agrotis A, Tipping P, Bobik A, Toh BH. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol. 2010;185(7):4410-4419. doi:10.4049/jimmunol.1000033</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ. B Cells and Humoral Immunity in Atherosclerosis. Circ Res. 2014;114(11):1743-1756. doi:10.1161/circresaha.113.301145</mixed-citation></ref></ref-list></back></article>
